ARS Pharmaceuticals第二季度每股收益（0.46），在线，销售额1571.7万美元，超过1377.6万美元的预期

ARS Pharmaceuticals (NASDAQ: SPRY) reported quarterly losses of $(0.46) per share which met the analyst consensus estimate. This is a 253.85 percent decrease over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $15.717 million which beat the analyst consensus estimate of $13.776 million by 14.09 percent. This is a 3.04K percent increase over sales of $500.000 thousand the same period last year.